11/4/2026

speaker
Grace
Conference Call Operator

Good day and thank you for standing by. Welcome to the Myriad Genetics Third Quarter 2026 Financial Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, Please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Matthew Scalo. Go ahead.

speaker
Matthew Scalo
Senior Vice President, Investor Relations

Good afternoon and welcome to the MIRI Genetics third quarter 2026 earnings call. During the call, we will review financial results we released today and afterwards we will host a Q&A session. Our earnings release was issued this afternoon on Form 8K and can be found on our website at investor.myriad.com. I'm Matt Scalo, Senior Vice President of Investor Relations. And on the call with me today are Sam Raha, our President and Chief Executive Officer, and Ben Wheeler, our Chief Financial Officer. Joining for Q&A will be Vishal Sikri, Executive Vice President of Commercial, and Mark Verratti, our Chief Operating Officer. This call can be heard live via webcast at investor.merit.com and a recording will be archived in the investor section of our website along with the slide presentation. Please note that some of the information presented today contains projections or other forward-looking statements regarding future events or the future financial performance of the company. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations for a variety of reasons. We refer you to the documents the company files from time to time with the SEC, specifically the company's annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in our projections or forward-looking statements. I'll now turn the call over to Sam.

speaker
Sam Raha
President and Chief Executive Officer

Thanks, Matt. Good afternoon, everyone, and thank you for joining us. I want to start by welcoming Vishal Sikri to our earnings call. Vishal joined Myriad in 2025 as our SVP of product and was recently promoted Executive Vice President of Commercial, where he is now overseeing sales, marketing, and product. Vishal has a deep understanding of molecular diagnostics and oncology, as well as extensive business and commercial leadership experience. As Matt mentioned, Vishal is here in the room and available to participate in the Q&A portion of our call today along with Mark Verratti. Before we discuss third quarter results, I want to start by framing the context for the last few months. We understand the key challenges that we've been facing, continued softness in our prenatal health business, reimbursement pressure on HCT, and financial stability, and we have been taking decisive actions to address the challenges. and I am pleased by the progress we're making on multiple fronts. To materially strengthen Myriad going forward, we've been advancing our work on a number of initiatives. First, we've done a rigorous review of our product portfolio to determine how to maximize shareholder value and sharpen Myriad's focus. This led to the definitive agreement to divest our prenatal health business, which we recently announced. Next, we have been working on a set of initiatives to address reimbursement pressures. Our increased revenue per test for the cancer care continuum business in Q3 compared to Q2 reflects our team's ongoing work and early progress with pair engagement and revenue cycle efforts. Next, we've been working on the Ascend initiative which we introduced on the second quarter call to modernize how we operate as a company to both better serve customers and increase our ability to win in the market while improving productivity, efficiency, and our cost structure. This initiative is about optimized processes and organizational design supported by new tools and technologies. We're working on Ascend with a leading consulting firm, and while this is a multi-year initiative, we've already started taking actions. We will share more about Ascend and its expected impact as we move into 2027. Finally, we've redoubled our focus on business execution and results to ensure we can demonstrate operational, commercial, and financial progress on a consistent quarterly basis. With that, let me dive into our third quarter performance and highlights. Third quarter total revenue of $202.7 million was supported by growing demand for our cancer care and mental health offerings, with 4% volume growth of cancer care continuum tests, and 3% volume growth of our mental health tests, offset by 11% decline in the volume of prenatal health tests. For average revenue per test, we reported an increase of 1% year-over-year in Q3, compared to a decrease of 9% year-over-year in Q2. In fact, Q3 revenue per HCT test, while down 6% year-over-year, improved 9% sequentially over Q2 of 2026. The improvement in total average revenue per test reflects test mix and early progress addressing payer friction through enhanced engagement and revenue cycle management initiatives. We outlined a number of these initiatives on our second quarter call, and Ben will share more about this later. While we are pleased with the results from these activities so far, we know that revenue cycle management requires unrelenting attention and engagement as conditions evolve. and let me reemphasize that HCT remains a highly profitable business line with attractive margins, strong cash generation and significant long-term volume growth opportunities. In terms of profitability, the sequential improvement of revenue per test flows through the P&L. Our gross margin of 67.9% improved 130 basis points compared to Q2 along with a meaningful quarter-over-quarter improvement in adjusted EBITDA of negative 5.3 million and adjusted EPS at negative 11 cents. On October 20th, we announced that Myriad has signed a definitive agreement to sell the prenatal health business to LabCorp. This is an all-cash deal for $210 million plus inventory, which values this business at 1.3 times trailing 12-month revenue. We are pleased with the outcome and early investor feedback has been unanimously positive as well. I'll speak further to the benefits of this transaction in a moment. Looking at the full year of 2026, given the steady volume growth of our cancer care continuum and mental health tests, along with improving average revenue per test in Q3 over Q2, we are raising the midpoint of our 2026 revenue guidance modestly. Total revenue guidance moved to a range of $780 to $790 million. This update reflects conservative assumptions related to prenatal health testing volume. Ben will share more on our guidance later. We expect the sale of the prenatal health business to unlock significant value for Myriad and our shareholders, resulting in a new Myriad that has materially strengthened financial profile in terms of revenue growth rate, profitability, and liquidity. Working with LabCorp, when the transaction closes, we expect a smooth transition that preserves uninterrupted patient access to our prenatal tests. and a good opportunity for our approximately 500 team members who will move to LabCorp to continue serving prenatal health care providers. Importantly, the transaction will enable the new myriad to be even more focused on the sizable, attractive cancer care continuum market opportunity. Now, turning to third quarter performance by business. In Q3, the cancer care continuum business generated revenue of $124 million, up 1% year-over-year, reflecting test volume growth of 4% to 98,000 tests, being offset by a 3% decline in average revenue per test. HCT volume grew 6% year-over-year, with volume growth in both the unaffected and affected population continuing to be strong. In fact, unaffected HCT in Q3 marked its highest volume record recorded in the last three years. We continue to drive steady volume growth in HCT enabled by a combination of our clinically relevant content, strong market position, and improving commercial execution. It's encouraging to see the continued guideline expansion for HCT, including the updates by NCCN earlier this year, for all patients with endometrial cancer and also for colorectal cancer and gastric cancers regardless of age and family history. Guideline expansion is expected to continue to support growth in years to come. For prostate cancer, we continue to receive positive feedback on Prolaris plus AI, which we launched mid-year. However, we believe our volume has been impacted by the NCCM guideline, which recommends blood-based biomarker testing and imaging in certain situations prior to biopsy. Turning to Precise MRD, we're pleased to report on the latest positive data using our tests. At the ESMO conference a couple of weeks ago, Our collaboration partner, the National Cancer Center Hospital East, presented data on the clinical significance of ultra-sensitive MRD testing using our precise MRD test in the assessment of colorectal cancer patients enrolled in the MONSTAR III study. While the overall study is still maturing, in this interim analysis, 91% of patients who recurred were MRD positive and precise MRD one month after surgery. Higher than has been reported with other assays and previous analyses. Further, the remaining 9% who recurred were identified as positive via serial testing. Approximately half of the post-surgery ctDNA positive results were detected at an ultrasensitive level, and 35% of patients who have recurred so far had their first positive detection at an ultrasensitive level. In essence, this illustrates the power of precise MRD for earlier detection to help inform medical management and can benefit patient care. We look forward to strong data readouts and additional presentations and publications in 2027. Regarding commercial availability, we have spoken about how we're engaging new customers at early access sites. In fact, just last week, I had the chance to personally meet with some Precise MRD customers to hear their input directly. For early access, we continue to closely monitor test utilization, customer experience, and our internal operational efficiency. We expect precise MRD reimbursement for breast cancer to begin first half of 2027 to be submitted to Moldex this summer. And consistent with past commentary, we would expect reimbursement for colorectal and renal cancer later in 2027. We intend to continue prudently managing testing demand until reimbursement is established. Turning now to mental health. In the third quarter, Genesight generated $40 million in revenue, up 2% year-over-year on 3% year-on-year volume growth. We continue to expand the ordering provider base, reaching over 40,000 ordering clinicians in the third quarter, and this steady volume growth reflects positive underlying demand and sales performance. We remain disciplined with a strong focus on capital efficiency while delivering growth with Genesight. Now moving to our prenatal health business. As I've already discussed the announcement of the sale, I'll be brief. In Q3, the prenatal health business generated revenue of $39 million, down 12% year-over-year, reflecting a modest decline of 1% in average revenue per test, while volume declined 11%. That being said, first team testing volume showed a nice ramp and we look forward to working closely with LabCorp to provide continuity prenatal testing for healthcare providers and patients. Finally, we've used this slide since the beginning of the year to track progress of key actions and milestones, product launches, publications and submissions. The check marks show that as we near the last part of the year, we have successfully completed the majority of these important milestones related to HCT, prostate cancer and precise MRD. and these actions will support our growth in cancer care continuum as we go forward. With that, I'll turn it over to our CFO, Ben Wheeler.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API